• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Anti-Aging
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

Verifying the Vaccine

Article

Chicago - As patient accrual to phase III trials of Canvaxin therapeutic polyvalent cancer vaccine nears the 1,000-mark, a randomized phase II trial of the vaccine was reported at the annual meeting of the American Society of Clinical Oncology. The trial used an immunostimulant to enhance the antibody response to a tumor-associated antigen (TA90) found on melanoma cells.

Related Videos
Related Content
Half of Patients With Psoriasis Receiving Placebo In Clinical Trials Report Adverse Events

Half of Patients With Psoriasis Receiving Placebo In Clinical Trials Report Adverse Events

Article
The Cutaneous Connection: Make Data-Driven Decisions For Personalized AD Treatment

The Cutaneous Connection: Make Data-Driven Decisions For Personalized AD Treatment

Podcast
Mobile Health Technologies In Studies of Actinic Keratosis Do Not Compromise Patient Safety, Research Article Says

Mobile Health Technologies In Studies of Actinic Keratosis Do Not Compromise Patient Safety, Research Article Says

Article
ReV Up Your Vitiligo Treatment Strategies

ReV Up Your Vitiligo Treatment Strategies

Podcast
Introducing Omar Noor, MD, FAAD: Dermatology Times' Newest Editorial Advisory Board Member

Introducing Omar Noor, MD, FAAD: Dermatology Times' Newest Editorial Advisory Board Member

Article
Atopic Dermatitis Identified as Possible Risk Factor for Headache Disorders, Migraine

Atopic Dermatitis Identified as Possible Risk Factor for Headache Disorders, Migraine

Article
© 2024 MJH Life Sciences

All rights reserved.